GlassScriptPhysician profile
Ann M Pagano
NPI 1679548663
$1,055.46
in general payments reported to CMS, 2019-2025
24 companies · $169 in 2025
The $169 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $31.81 · 2021: $73.19 · 2022: $210 · 2023: $159 · 2024: $94.64 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $403 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $403.34 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $145.83 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $128.49 | 2019-2022 | |
| Pfizer INC. | $113.51 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.14 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $90.06 | 2022-2025 | |
| Organon LLC | $59.33 | 2023-2024 | Jada System |
| Pacira Pharmaceuticals Incorporated | $45.09 | 2025 | Exparel |
| Therapeuticsmd, INC. | $41.64 | 2019-2022 | |
| Hologic Sales and Service, LLC | $37.00 | 2024-2025 | Thinprep 2000 Processor, Aptima, Novasure |
| Coloplast Corp | $34.56 | 2021 | |
| Dilon Technologies, INC. | $28.99 | 2025 | Hemoblast Bellows |
| Allergan, INC. | $27.92 | 2019 | |
| Millicent US INC | $27.57 | 2019 | |
| Alydia Health | $25.81 | 2021 | |
| Smith+Nephew, INC. | $18.50 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $18.10 | 2025 | Slynd |
| Daiichi Sankyo INC. | $15.27 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.81 | 2019 | |
| Myovant Sciences INC. | $14.77 | 2022 | |
| Coopersurgical, INC. | $14.63 | 2023 | Paragard T 380a |
| Sumitomo Pharma America, INC. | $14.35 | 2023 | Myfembree |
| Evofem Biosciences, INC. | $13.55 | 2022 | |
| Agile Therapeutics, INC. | $13.53 | 2022 | |
| Avion Pharmaceuticals | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Pagano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.